Physician profile
Heather Johnson
NPI 1629529565
$8,140.35
in general payments reported to CMS, 2019-2025
29 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,035 · 2022: $1,996 · 2023: $1,573 · 2024: $1,294 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.77 |
| Education | $165.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,317.37 | 2021-2025 | Opzelura, Opzelura |
| Journey Medical Corporation | $725.92 | 2021-2025 | |
| Lilly USA, LLC | $586.84 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $548.66 | 2021-2025 | Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $479.92 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $473.96 | 2021-2025 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $464.56 | 2021-2023 | Jublia |
| Janssen Biotech, INC. | $444.03 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $417.09 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $399.77 | 2021-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $389.61 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $340.24 | 2022-2025 | Sotyktu |
| Pfizer INC. | $309.10 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $188.14 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $163.26 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $142.50 | 2024-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $139.45 | 2021 | |
| Abbvie INC. | $135.44 | 2021-2025 | |
| Amgen INC. | $82.83 | 2024-2025 | Otezla, Otezla |
| Sebela Pharmaceuticals INC. | $76.14 | 2021-2023 | Pramosone, Naftin |
| Ucb, INC. | $66.75 | 2021-2023 | Cimzia |
| Botanix Sb INC | $49.75 | 2025 | Sofdra |
| Epi Health, LLC | $46.84 | 2022 | |
| Organon LLC | $46.27 | 2025 | |
| Merz North America, INC. | $31.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.02 | 2021 | |
| Cipher Pharmaceuticals US LLC | $18.99 | 2025 | Natroba, Spinosad |
| Solta Medical, A Division of Bausch Health US, LLC | $16.77 | 2023 | |
| Biofrontera INC. | $16.07 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.